Shares of Clene Inc. (NASDAQ:CLNN – Free Report) are scheduled to reverse split on Thursday, July 11th. The 1-20 reverse split was announced on Thursday, July 11th. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, July 11th.
Clene Stock Down 21.5 %
NASDAQ:CLNN traded down $0.07 during trading hours on Tuesday, hitting $0.27. 2,714,955 shares of the stock traded hands, compared to its average volume of 835,770. Clene has a fifty-two week low of $0.25 and a fifty-two week high of $0.85. The company has a current ratio of 1.23, a quick ratio of 1.22 and a debt-to-equity ratio of 1.66. The firm has a market cap of $35.00 million, a price-to-earnings ratio of -0.59 and a beta of 0.46. The firm has a 50 day moving average price of $0.37 and a 200 day moving average price of $0.39.
Clene (NASDAQ:CLNN – Get Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.09) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.09). Clene had a negative net margin of 7,873.23% and a negative return on equity of 224.28%. The business had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.16 million. Equities research analysts anticipate that Clene will post -0.34 earnings per share for the current year.
Wall Street Analysts Forecast Growth
View Our Latest Stock Analysis on Clene
Clene Company Profile
Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
Read More
- Five stocks we like better than Clene
- Ride Out The Recession With These Dividend KingsĀ
- 3 Insider-Buy Stocks to Add to Your Watchlist Now
- 5 Top Rated Dividend Stocks to Consider
- Commvault Stock: AI Cybersecurity Giant Ready to Double Again
- Pros And Cons Of Monthly Dividend Stocks
- Intuit Stock Ready to Soar: RBC Sees Big Upside with GenAI
Receive News & Ratings for Clene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clene and related companies with MarketBeat.com's FREE daily email newsletter.